Telephone

ADT Announces Launch of Secondary Public Offering of Common Stock and Concurrent Share Repurchase

Retrieved on: 
Wednesday, March 6, 2024

The underwriters will have a 30-day option to purchase up to an additional 8,250,000 shares of common stock from the Selling Stockholders.

Key Points: 
  • The underwriters will have a 30-day option to purchase up to an additional 8,250,000 shares of common stock from the Selling Stockholders.
  • The Company is not selling any shares and will not receive any proceeds from the proposed offering.
  • In addition, ADT has authorized the concurrent purchase from the underwriters of 15,000,000 shares of common stock as part of the secondary public offering (the “Share Repurchase”) subject to the completion of the offering.
  • The Share Repurchase is part of the Company’s existing $350 million share repurchase program.

DEADLINE ALERT for INMD, AMPL, NOVA, DKS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Wednesday, March 6, 2024

BENSALEM, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Wednesday, March 6, 2024

PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced the pricing on March 5, 2024 of an underwritten public offering of 8,620,690 shares of its common stock at a public offering price of $29.00 per share, before deducting underwriting discounts and commissions.

Key Points: 
  • PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced the pricing on March 5, 2024 of an underwritten public offering of 8,620,690 shares of its common stock at a public offering price of $29.00 per share, before deducting underwriting discounts and commissions.
  • In addition, BridgeBio has granted the underwriters a 30-day option to purchase up to an additional 1,293,103 shares of its common stock on the same terms and conditions.
  • All of the shares in the offering to be sold by BridgeBio.
  • The shares of common stock are being offered by BridgeBio pursuant to an effective shelf registration statement on Form S-3ASR (File No.

Viper Energy Announces Pricing of Secondary Common Stock Offering by Diamondback Energy, Inc.

Retrieved on: 
Wednesday, March 6, 2024

MIDLAND, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ: VNOM) (“Viper”) announced today the pricing of an underwritten public offering of 11,500,000 shares of its Class A common stock (the “Secondary Offering”) by Viper’s parent, Diamondback Energy, Inc. (the “Secondary Stockholder”).

Key Points: 
  • MIDLAND, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ: VNOM) (“Viper”) announced today the pricing of an underwritten public offering of 11,500,000 shares of its Class A common stock (the “Secondary Offering”) by Viper’s parent, Diamondback Energy, Inc. (the “Secondary Stockholder”).
  • The Secondary Offering is expected to close on March 8, 2024, subject to customary closing conditions.
  • J.P. Morgan, Barclays, Evercore ISI and Goldman Sachs & Co. LLC are acting as joint book-running managers for the Secondary Offering.
  • The Secondary Offering may only be made by means of a prospectus supplement and related base prospectus.

Landsea Homes Announces Pricing of Secondary Common Stock Offering

Retrieved on: 
Wednesday, March 6, 2024

DALLAS, March 06, 2024 (GLOBE NEWSWIRE) -- Landsea Homes Corporation (Nasdaq: LSEA) (“Landsea Homes” or the “Company”), a publicly traded residential homebuilder, announced today the pricing of the previously announced underwritten secondary offering by its largest stockholder, Landsea Holdings Corporation (the “Selling Stockholder”) of 2,434,783 shares of the Company’s common stock, at a price of $11.60 per share (before underwriting discounts and commissions) (the “Offering”).

Key Points: 
  • DALLAS, March 06, 2024 (GLOBE NEWSWIRE) -- Landsea Homes Corporation (Nasdaq: LSEA) (“Landsea Homes” or the “Company”), a publicly traded residential homebuilder, announced today the pricing of the previously announced underwritten secondary offering by its largest stockholder, Landsea Holdings Corporation (the “Selling Stockholder”) of 2,434,783 shares of the Company’s common stock, at a price of $11.60 per share (before underwriting discounts and commissions) (the “Offering”).
  • The Selling Stockholder has granted the underwriters a 30-day option to purchase up to 365,217 additional shares of the Company's common stock.
  • The Offering is expected to close on March 8, 2024, subject to the satisfaction of customary closing conditions.
  • The Company is not offering any shares of its common stock in the Offering and will not receive any of the proceeds from the sale of the shares offered by the Selling Stockholder.

Akero Therapeutics Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Wednesday, March 6, 2024

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $29.00 per share.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $29.00 per share.
  • All of the shares in the offering are being offered by Akero Therapeutics.
  • In addition, Akero Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • The shares of common stock are being offered by Akero Therapeutics pursuant to an automatically effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC).

PROPETRO ALERT: Bragar Eagel & Squire, P.C. is Investigating ProPetro Holding Corp. on Behalf of ProPetro Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, March 6, 2024

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against ProPetro Holding Corp. (“ProPetro” or the “Company”) (NYSE: PUMP) on behalf of ProPetro stockholders.

Key Points: 
  • NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against ProPetro Holding Corp. (“ProPetro” or the “Company”) (NYSE: PUMP) on behalf of ProPetro stockholders.
  • Our investigation concerns whether ProPetro has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Click here to participate in the action.
  • On this news, shares of ProPetro Holding Corp. dropped more than 5% in intraday trading on March 4, 2024.

BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024

Retrieved on: 
Wednesday, March 6, 2024

MAINZ, Germany, March 6, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2023 on Wednesday, March 20, 2024.

Key Points: 
  • MAINZ, Germany, March 6, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2023 on Wednesday, March 20, 2024.
  • Additionally, the Company will host a conference call and webcast that day at 8:00 a.m.
  • ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
  • A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.

CoreCivic Announces Upsizing and Pricing of $500 Million 8.25% Senior Notes Due 2029

Retrieved on: 
Tuesday, March 5, 2024

BRENTWOOD, Tenn., March 05, 2024 (GLOBE NEWSWIRE) -- CoreCivic, Inc. (NYSE: CXW) (“CoreCivic”) announced today that it successfully upsized and priced its offering of $500 million aggregate principal amount of 8.25% senior notes due 2029 (the “Notes”).

Key Points: 
  • BRENTWOOD, Tenn., March 05, 2024 (GLOBE NEWSWIRE) -- CoreCivic, Inc. (NYSE: CXW) (“CoreCivic”) announced today that it successfully upsized and priced its offering of $500 million aggregate principal amount of 8.25% senior notes due 2029 (the “Notes”).
  • The aggregate principal amount of the Notes to be issued in the offering was increased to $500 million from the previously announced $450 million.
  • The Notes will be senior unsecured obligations of CoreCivic and will be guaranteed on a senior unsecured basis by all of CoreCivic’s subsidiaries that guarantee its existing senior secured credit facilities, 4.75% senior unsecured notes due October 2027 and 8.25% senior unsecured notes due 2026 (the “2026 Notes”).
  • The aggregate net proceeds from the sale of the Notes are expected to be approximately $490.3 million, after deducting the underwriting discounts and estimated offering expenses.

Landsea Homes Announces Secondary Common Stock Offering

Retrieved on: 
Tuesday, March 5, 2024

DALLAS, March 05, 2024 (GLOBE NEWSWIRE) -- Landsea Homes Corporation (Nasdaq: LSEA) (“Landsea Homes” or the “Company”), a publicly traded residential homebuilder, announced today that its largest stockholder, Landsea Holdings Corporation (the “Selling Stockholder”), has commenced a secondary offering of 2,434,783 shares of the Company’s common stock (the “Offering”).

Key Points: 
  • DALLAS, March 05, 2024 (GLOBE NEWSWIRE) -- Landsea Homes Corporation (Nasdaq: LSEA) (“Landsea Homes” or the “Company”), a publicly traded residential homebuilder, announced today that its largest stockholder, Landsea Holdings Corporation (the “Selling Stockholder”), has commenced a secondary offering of 2,434,783 shares of the Company’s common stock (the “Offering”).
  • The Selling Stockholder will also grant the underwriters a 30-day option to purchase up to an additional 365,217 shares of common stock.
  • B. Riley Securities and BofA Securities are acting as joint bookrunning managers in the Offering.
  • The Company is not offering any shares of its common stock in the Offering and will not receive any of the proceeds from the sale of the shares offered by the Selling Stockholder.